Cornerstone Therapeutics (NASDAQ: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing niche respiratory products, today announced findings from a study comparing all-cause, in-hospital mortality in more than 14,000 preterm infants with respiratory distress syndrome (RDS). The retrospective study evaluated Cornerstone’s CUROSURF ® (poractant alfa) compared to Infasurf ® (calfactant) and Survanta ® (beractant). Overall, CUROSURF treatment for RDS was associated with a significantly reduced likelihood of death compared to Infasurf, and a trend toward reduced mortality when compared with Survanta. The findings were published in the September 1, 2011 online issue of the Journal of Perinatology.
“Cornerstone is extremely pleased with the results of this study. This research, especially among the smallest infants, reinforces why CUROSURF is the market leader in the U.S. and worldwide, and why we continue to see successful hospital conversions to CUROSURF therapy,” said Craig A. Collard, Cornerstone’s Chief Executive Officer. “When paired with CUROSURF’s existing, extensive clinical evidence, we believe these data will give neonatologists further confidence that CUROSURF is an appropriate choice to treat babies with RDS.”
Cornerstone licensed CUROSURF U.S. rights from Chiesi Farmaceutici S.p.A. (Parma, Italy) as part of a broader transaction it completed with Chiesi in May 2009.
About Respiratory Distress SyndromeNeonatal RDS is a complication of prematurity that makes breathing difficult for infants with underdeveloped lungs. The condition is caused by a lack of adequate endogenous surfactant - a protective substance that helps to reduce surface tension in the lungs. Without adequate surfactant, it is extremely difficult for infants to fully inflate their lungs and to avoid alveolar collapse. With approximately 550,000 premature births in the United States per year 1, the National Heart Lung and Blood Institute reports that 10 of every 100 premature babies develop neonatal RDS, with nearly all infants born before 28 weeks of pregnancy developing RDS 2. To treat this condition, physicians will often administer an exogenous surfactant shortly after birth. This surfactant is meant to reduce surface tension, helping to improve oxygenation and lung function. Today, physicians have a choice of three different animal-derived surfactants in the United States: CUROSURF, Infasurf or Survanta. Each features a unique composition, volume requirements and surfactant dosage. About the Study The study was a retrospective, observational, cohort study comparing all-cause, in-hospital mortality in 14,173 preterm infants with RDS treated with one of three surfactants between 2005 and 2009. Data were collected from the research database maintained by the Charlotte, N.C.-based Premier healthcare alliance. The Premier Hospital Database is a large U.S. hospital-based database, containing information on approximately 5.5 million annual hospital discharges (approximately one-fifth of all acute care hospitalizations in the U.S.) with day-by-day service level detail.This study included discharge data from 236 hospitals across the United States. Key study findings are as follows:
- When compared to infants treated with CUROSURF, the likelihood of mortality was 49.6 percent greater for Infasurf patients (p=0.043), and 37.0 percent greater for Survanta patients (p=0.053).
- There were no differences in mortality observed between the Infasurf and Survanta groups (p=0.626).
- The unadjusted mortality rates were lowest for the infants treated with CUROSURF (3.61 percent), followed by Survanta (4.58 percent) and Infasurf (5.95 percent).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV